The marketing authorisation for Victrelis has been withdrawn at the request of the marketing-authorisation holder.
Victrelis : EPAR - Summary for the public (PDF/513.73 KB)
First published: 03/08/2011
Last updated: 31/07/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Hepatitis C, Chronic
|Anatomical therapeutic chemical (ATC) code||
Merck Sharp Dohme Ltd
|Date of issue of marketing authorisation valid throughout the European Union||
28/06/2017 Victrelis - EMEA/H/C/002332 - II/0042
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Antivirals for systemic use
Victrelis is indicated for the treatment of chronic hepatitis-C (CHC) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.